Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Center, Cross-Sectional Study of PET-MRI with (11)C-UCB-J (synaptic vesicle protein 2A), (18)F-MK-6240 (tau deposition), and (11)C-Pittsburgh compound B (β-amyloid) and neuropsychological assessment

Trial Profile

A Single-Center, Cross-Sectional Study of PET-MRI with (11)C-UCB-J (synaptic vesicle protein 2A), (18)F-MK-6240 (tau deposition), and (11)C-Pittsburgh compound B (β-amyloid) and neuropsychological assessment

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Florquinitau F18 (Primary)
  • Indications Amnesia; Mild cognitive impairment
  • Focus Diagnostic use; Pharmacodynamics

Most Recent Events

  • 17 Jun 2020 New trial record
  • 03 Jun 2020 Results published in the Neurology Journal.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top